30 years of second-generation antiseizure medications: impact and future perspectives

This review discusses the overall effect of second-generation anti-seizure medications on epilepsy management and the extent by which these drugs have overcome the shortcomings of older, first-generation medications.

SPS commentary:

Separately, JAMA Neurology has published data from a 30-year longitudinal cohort study of 1795 patients with newly diagnosed and treated epilepsy at a specialist clinic in Glasgow, which showed the intolerable adverse effect rate observed with older antiepileptics, was not improved despite the increased using of second-generations antiseizure medications.


The Lancet Neurology

Resource links:

JAMA Neurology